Public Release: 

Very low transmission of HIV within couples receiving both ART and PrEP

PLOS

Providing HIV medication to both members of a couple may substantially reduce the risk of transmission within that couple, according to a study in PLOS Medicine. Jared Baeten of the University of Washington and colleagues conducted a prospective implementation study to test the feasibility and acceptability of a program to initially offer antiretroviral medications to both members of couples in which one member was HIV-positive and the other was HIV-negative (HIV-serodiscordant couples). The researchers enrolled 1013 heterosexual HIV-serodiscordant couples in Kenya and Uganda who were at high risk of transmission based on behavioral and biological characteristics. Antiretroviral therapy (ART), which by suppressing HIV replication both controls progression of HIV and reduces infectiousness, was provided to the HIV-infected partner. To reduce susceptibility to infection prior to viral suppression in the HIV-infected partner, the HIV-uninfected partners were offered antiretroviral drugs for pre-exposure prophylaxis (PrEP) prior to and during the first 6 months of ART. The researchers followed the couples for an average of about one year per couple. The primary goals of the study were to evaluate implementation of this delivery model, however, part-way through the anticipated delivery period, it became clear that HIV transmission rates were considerably lower than would have been anticipated. In addition to high acceptability and adherence, the dual treatment regimen showed rates of HIV transmission 96% lower than estimated rates of transmission in a simulated cohort of serodiscordant couples.

The researchers note that conclusions are limited because this study does not include a concurrent comparison population for HIV transmission, as it would not have been ethical to enroll a control population and not offer access to ART and PrEP. Nevertheless, the findings suggest this may be a promising strategy for in the fight to reverse the HIV epidemic. The authors say: "The results of this project demonstrate that an integrated strategy of ART and PrEP can be delivered feasibly to a high-risk African population and result in almost complete protection from HIV-1 transmission."

###

Research Article

Funding:

The Partners Demonstration Project was funded by the National Institute of Mental Health of the US National Institutes of Health (grant R01 MH095507), the Bill & Melinda Gates Foundation (grant OPP1056051), and through the US Agency for International Development (cooperative agreement AID-OAA-A-12-00023). Gilead Sciences donated the PrEP medication but had no role in data collection or analysis. The results and interpretation presented here do not necessarily reflect the views of the study funders. The study funders had no role in study design, data collection, data analysis, data interpretation, or writing of the report.

Competing Interests:

All authors have read the journal's policy and have the following competing interests: Gilead Sciences donated the PrEP medication used in this study. CH received prior funding (05/01/09-04/30/10) for a pharmacokinetics study of TDF in the colon and female genital tract from Gilead Sciences and has a patent pending using a different formulation of the drug used in this study.

Citation:

Baeten JM, Heffron R, Kidoguchi L, Mugo NR, Katabira E, Bukusi EA, et al. (2016) Integrated Delivery of Antiretroviral Treatment and Pre-exposure Prophylaxis to HIV-1-Serodiscordant Couples: A Prospective Implementation Study in Kenya and Uganda. PLoS Med 13(8): e1002099. doi:10.1371/journal.pmed.1002099

Author Affiliations:

Department of Global Health, University of Washington, Seattle, Seattle, Washington, United States of America
Department of Medicine, University of Washington, Seattle, Seattle, Washington, United States of America
Department of Epidemiology, University of Washington, Seattle, Seattle, Washington, United States of America
Centre for Clinical Research, Kenya Medical Research Institute, Nairobi, Kenya
Infectious Disease Institute, Makerere University, Kampala, Uganda
Centre for Microbiology Research, Kenya Medical Research Institute, Nairobi, Kenya
Kabwohe Clinical Research Center, Kabwohe, Uganda
Massachusetts General Hospital, Boston, Massachusetts, United States of America
College of Health Sciences, Jomo Kenyatta University of Agriculture and Technology, Nairobi, Kenya
Department of Medicine, Johns Hopkins University, Baltimore, Maryland, United States of America
Department of Global Health and Social Medicine, Harvard Medical School, Boston, Massachusetts, United States of America
Harvard Global, Cambridge, Massachusetts, United States of America
Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, United States of America

IN YOUR COVERAGE PLEASE USE THIS URL TO PROVIDE ACCESS TO THE FREELY AVAILABLE PAPER:

http://journals.plos.org/plosmedicine/article?id=10.1371/journal.pmed.1002099

Contact:

Jared M Baeten

University of Washington
Global Health, Medicine and Epidemiology
325 Ninth Ave
Box 359927
Seattle, 98104
UNITED STATES
jbaeten@UW.edu
206-520-3808

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.